Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis

Seung Yul Lee, Byeong Keuk Kim, Jung Sun Kim, Myeong Ki Hong, Deok Kyu Cho, Junghan Yoon, Dong Woon Jeon, Nam Ho Lee, Hyuck Moon Kwon, Yangsoo Jang

Research output: Contribution to journalArticle

Abstract

Objectives We aimed to evaluate the mid-term outcomes of resolute zotarolimus-eluting stent (R-ZES) implantation for in-stent restenosis (ISR). Background There has been a paucity of data regarding the effects of new-generation drug-eluting stent to treat ISR. Methods From 2009 to 2010, a total of 98 patients with 98 ISR lesions were prospectively enrolled after R-ZES implantation for the treatment of ISR. Among 98 patients, 73 patients underwent follow-up angiography at 9 months. Serial intravascular ultrasound (IVUS) at both postprocedure and 9 months was evaluated in 55 patients. The overlapped segment of R-ZES was defined as the portion of R-ZES superimposed on previous stent. Results Late loss and binary restenosis rate were 0.3 ± 0.5 mm and 5.5% at 9 months. On IVUS, the percentage of neointimal volume and maximum percentage of neointimal area were 3.9 ± 6.3% and 17.3 ± 15.5%, respectively. There was no significant change of vessel volume index between postprocedure and 9 months (16.9 ± 4.7 mm3/mm vs. 17.1 ± 4.6 mm3/mm, P = 0.251). Late-acquired incomplete stent apposition was observed in 5 (5/55, 9.1%) cases. Compared with nonoverlapped segments of R-ZES, the overlapped did not show larger neointimal volume index (0.3 ± 0.5 mm3/mm vs. 0.2 ± 0.3 mm3/mm, P = 0.187) on 9-month IVUS. During follow-up (median, 353 days), repeat target-lesion revascularization was performed in four cases, but there were no death or stent thrombosis. Conclusions This study suggested that R-ZES implantation for the treatment of ISR was effective up to 9 months and showed favorable vascular responses on serial IVUS assessment.

Original languageEnglish
Pages (from-to)543-549
Number of pages7
JournalJournal of Interventional Cardiology
Volume26
Issue number6
DOIs
Publication statusPublished - 2013 Dec

Fingerprint

Stents
Therapeutics
zotarolimus
Cohort Effect
Drug-Eluting Stents
Blood Vessels
Angiography
Thrombosis

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Lee, Seung Yul ; Kim, Byeong Keuk ; Kim, Jung Sun ; Hong, Myeong Ki ; Cho, Deok Kyu ; Yoon, Junghan ; Jeon, Dong Woon ; Lee, Nam Ho ; Kwon, Hyuck Moon ; Jang, Yangsoo. / Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis. In: Journal of Interventional Cardiology. 2013 ; Vol. 26, No. 6. pp. 543-549.
@article{95818437d08b4fe6b000c2829e9db30a,
title = "Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis",
abstract = "Objectives We aimed to evaluate the mid-term outcomes of resolute zotarolimus-eluting stent (R-ZES) implantation for in-stent restenosis (ISR). Background There has been a paucity of data regarding the effects of new-generation drug-eluting stent to treat ISR. Methods From 2009 to 2010, a total of 98 patients with 98 ISR lesions were prospectively enrolled after R-ZES implantation for the treatment of ISR. Among 98 patients, 73 patients underwent follow-up angiography at 9 months. Serial intravascular ultrasound (IVUS) at both postprocedure and 9 months was evaluated in 55 patients. The overlapped segment of R-ZES was defined as the portion of R-ZES superimposed on previous stent. Results Late loss and binary restenosis rate were 0.3 ± 0.5 mm and 5.5{\%} at 9 months. On IVUS, the percentage of neointimal volume and maximum percentage of neointimal area were 3.9 ± 6.3{\%} and 17.3 ± 15.5{\%}, respectively. There was no significant change of vessel volume index between postprocedure and 9 months (16.9 ± 4.7 mm3/mm vs. 17.1 ± 4.6 mm3/mm, P = 0.251). Late-acquired incomplete stent apposition was observed in 5 (5/55, 9.1{\%}) cases. Compared with nonoverlapped segments of R-ZES, the overlapped did not show larger neointimal volume index (0.3 ± 0.5 mm3/mm vs. 0.2 ± 0.3 mm3/mm, P = 0.187) on 9-month IVUS. During follow-up (median, 353 days), repeat target-lesion revascularization was performed in four cases, but there were no death or stent thrombosis. Conclusions This study suggested that R-ZES implantation for the treatment of ISR was effective up to 9 months and showed favorable vascular responses on serial IVUS assessment.",
author = "Lee, {Seung Yul} and Kim, {Byeong Keuk} and Kim, {Jung Sun} and Hong, {Myeong Ki} and Cho, {Deok Kyu} and Junghan Yoon and Jeon, {Dong Woon} and Lee, {Nam Ho} and Kwon, {Hyuck Moon} and Yangsoo Jang",
year = "2013",
month = "12",
doi = "10.1111/joic.12073",
language = "English",
volume = "26",
pages = "543--549",
journal = "Journal of Interventional Cardiology",
issn = "0896-4327",
publisher = "Wiley-Blackwell",
number = "6",

}

Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis. / Lee, Seung Yul; Kim, Byeong Keuk; Kim, Jung Sun; Hong, Myeong Ki; Cho, Deok Kyu; Yoon, Junghan; Jeon, Dong Woon; Lee, Nam Ho; Kwon, Hyuck Moon; Jang, Yangsoo.

In: Journal of Interventional Cardiology, Vol. 26, No. 6, 12.2013, p. 543-549.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis

AU - Lee, Seung Yul

AU - Kim, Byeong Keuk

AU - Kim, Jung Sun

AU - Hong, Myeong Ki

AU - Cho, Deok Kyu

AU - Yoon, Junghan

AU - Jeon, Dong Woon

AU - Lee, Nam Ho

AU - Kwon, Hyuck Moon

AU - Jang, Yangsoo

PY - 2013/12

Y1 - 2013/12

N2 - Objectives We aimed to evaluate the mid-term outcomes of resolute zotarolimus-eluting stent (R-ZES) implantation for in-stent restenosis (ISR). Background There has been a paucity of data regarding the effects of new-generation drug-eluting stent to treat ISR. Methods From 2009 to 2010, a total of 98 patients with 98 ISR lesions were prospectively enrolled after R-ZES implantation for the treatment of ISR. Among 98 patients, 73 patients underwent follow-up angiography at 9 months. Serial intravascular ultrasound (IVUS) at both postprocedure and 9 months was evaluated in 55 patients. The overlapped segment of R-ZES was defined as the portion of R-ZES superimposed on previous stent. Results Late loss and binary restenosis rate were 0.3 ± 0.5 mm and 5.5% at 9 months. On IVUS, the percentage of neointimal volume and maximum percentage of neointimal area were 3.9 ± 6.3% and 17.3 ± 15.5%, respectively. There was no significant change of vessel volume index between postprocedure and 9 months (16.9 ± 4.7 mm3/mm vs. 17.1 ± 4.6 mm3/mm, P = 0.251). Late-acquired incomplete stent apposition was observed in 5 (5/55, 9.1%) cases. Compared with nonoverlapped segments of R-ZES, the overlapped did not show larger neointimal volume index (0.3 ± 0.5 mm3/mm vs. 0.2 ± 0.3 mm3/mm, P = 0.187) on 9-month IVUS. During follow-up (median, 353 days), repeat target-lesion revascularization was performed in four cases, but there were no death or stent thrombosis. Conclusions This study suggested that R-ZES implantation for the treatment of ISR was effective up to 9 months and showed favorable vascular responses on serial IVUS assessment.

AB - Objectives We aimed to evaluate the mid-term outcomes of resolute zotarolimus-eluting stent (R-ZES) implantation for in-stent restenosis (ISR). Background There has been a paucity of data regarding the effects of new-generation drug-eluting stent to treat ISR. Methods From 2009 to 2010, a total of 98 patients with 98 ISR lesions were prospectively enrolled after R-ZES implantation for the treatment of ISR. Among 98 patients, 73 patients underwent follow-up angiography at 9 months. Serial intravascular ultrasound (IVUS) at both postprocedure and 9 months was evaluated in 55 patients. The overlapped segment of R-ZES was defined as the portion of R-ZES superimposed on previous stent. Results Late loss and binary restenosis rate were 0.3 ± 0.5 mm and 5.5% at 9 months. On IVUS, the percentage of neointimal volume and maximum percentage of neointimal area were 3.9 ± 6.3% and 17.3 ± 15.5%, respectively. There was no significant change of vessel volume index between postprocedure and 9 months (16.9 ± 4.7 mm3/mm vs. 17.1 ± 4.6 mm3/mm, P = 0.251). Late-acquired incomplete stent apposition was observed in 5 (5/55, 9.1%) cases. Compared with nonoverlapped segments of R-ZES, the overlapped did not show larger neointimal volume index (0.3 ± 0.5 mm3/mm vs. 0.2 ± 0.3 mm3/mm, P = 0.187) on 9-month IVUS. During follow-up (median, 353 days), repeat target-lesion revascularization was performed in four cases, but there were no death or stent thrombosis. Conclusions This study suggested that R-ZES implantation for the treatment of ISR was effective up to 9 months and showed favorable vascular responses on serial IVUS assessment.

UR - http://www.scopus.com/inward/record.url?scp=84890121718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890121718&partnerID=8YFLogxK

U2 - 10.1111/joic.12073

DO - 10.1111/joic.12073

M3 - Article

C2 - 24308658

AN - SCOPUS:84890121718

VL - 26

SP - 543

EP - 549

JO - Journal of Interventional Cardiology

JF - Journal of Interventional Cardiology

SN - 0896-4327

IS - 6

ER -